Product image of Myrelez (Lanreotide Acetate) supplied by GNH India

Myrelez

Active Ingredient:
Lanreotide Acetate
Origin:
EU

Myrelez (Lanreotide Acetate)

Lanreotide Acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a subcutaneous injection for subcutaneous use. It is indicated for adult patients who require long‑term suppression of excess growth hormone and related hormonal activity, and it is employed to control hormone‑secreting tumors such as acromegaly and gastroenteropancreatic neuroendocrine tumors.

GNH India supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide with adherence to stringent quality standards, regulatory approvals and reliable cold‑chain logistics where required.

Manufacturer / TM Owner

Amdipharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myrelez (lanreotide acetate) is a somatostatin analog that targets hormone‑secreting neuroendocrine tumors and related endocrine disorders.

  • Acromegaly: Provides sustained suppression of growth hormone and insulin‑like growth factor‑1, leading to reduction of soft‑tissue swelling, joint pain and cardiovascular risk.
  • Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs): Limits tumor proliferation and decreases secretion of vasoactive peptides, helping to control flushing, diarrhea and disease progression.

How It Works

  • Lanreotide acetate binds with high affinity to somatostatin receptors, primarily subtypes sst2 and sst5, on pituitary and neuroendocrine cells. Receptor activation inhibits adenylate cyclase and calcium influx, suppressing secretion of growth hormone, insulin‑like growth factor‑1 and various gastrointestinal peptides. This blockade reduces cellular proliferation and hormone‑mediated symptoms associated with acromegaly and gastroenteropancreatic neuroendocrine tumors. The prolonged receptor engagement achieved by the depot formulation maintains therapeutic levels for weeks after a single subcutaneous injection.

Side Effects

Lanreotide acetate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Injection site pain: Mild discomfort or erythema at the injection site.
  • Diarrhea: Loose stools occurring shortly after dosing.
  • Nausea: Transient feeling of queasiness.
  • Abdominal pain: Cramp‑like discomfort in the abdomen.
  • Headache: Mild to moderate head pain.
  • Hyperglycemia: Elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects

  • Gallbladder disease: Biliary sludge or cholelithiasis leading to gallstone formation.
  • Pancreatitis: Inflammation of the pancreas presenting with severe abdominal pain.
  • Cardiac arrhythmias: Irregular heart rhythms requiring medical attention.
  • Severe allergic reactions: Anaphylaxis or angioedema.

Precautions & Warnings

When prescribing Myrelez, clinicians should consider several precautionary measures to ensure safe use.

  • Renal function: Assess kidney function before initiating therapy and monitor periodically.
  • Hepatic impairment: Use with caution in patients with liver disease, adjusting monitoring as needed.
  • Diabetes mellitus: Monitor blood glucose closely, as the drug may worsen hyperglycemia.
  • Gallbladder status: Evaluate for pre‑existing gallstones or biliary disease before treatment.
  • Pregnancy and lactation: Avoid use during pregnancy and breastfeeding unless benefits outweigh risks.
  • Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Avoid Interactions

Lanreotide acetate can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

  • Cyclosporine: May increase lanreotide plasma concentrations, raising risk of adverse effects.
  • Somatostatin analogs combination: Concurrent use can lead to additive hormonal suppression.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: Lanreotide may impair glucose control, requiring dose adjustments.
  • Hormonal contraceptives: Potential reduction in contraceptive effectiveness.
  • Octreotide: Overlapping mechanisms may increase gastrointestinal side effects.
  • Digoxin: Possible alteration in drug levels; monitor therapeutic range.

Frequently Asked Questions

Myrelez, containing lanreotide acetate, is prescribed for the long‑term management of adult patients with acromegaly and for controlling tumor growth and hormone‑related symptoms in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). It works by suppressing excess hormone secretion from these endocrine tumors.

Lanreotide acetate binds selectively to somatostatin receptor subtypes sst2 and sst5 on pituitary and neuroendocrine cells. Activation of these receptors inhibits adenylate cyclase and calcium influx, reducing the release of growth hormone, IGF‑1 and various gastrointestinal peptides, thereby limiting tumor proliferation and hormone‑mediated effects.

The dosing regimen for Myrelez is individualized by the treating physician based on the patient’s clinical condition, disease severity and response to therapy. The prescriber determines the appropriate dose, injection interval and any necessary adjustments, following current clinical guidelines and product labeling.

The safety of lanreotide acetate in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Myrelez, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Myrelez (lanreotide acetate) and other long‑acting somatostatin analogs such as octreotide LAR share the same mechanism of receptor activation but differ in dosing intervals, formulation and pharmacokinetic profile. Lanreotide is administered as a deep‑subcutaneous injection every 4–8 weeks, offering a convenient schedule for many patients.

Myrelez should be stored at 2–8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and potency.

Myrelez is given as a deep subcutaneous injection, typically in the abdomen, thigh or upper arm. A healthcare professional prepares the pre‑filled syringe or vial according to the manufacturer’s instructions and administers the dose at the prescribed interval, usually every 4 to 8 weeks.

Serious adverse events reported with lanreotide acetate include gallbladder disease (biliary sludge or gallstones), pancreatitis, severe hyperglycemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored for abdominal pain, jaundice, elevated blood glucose and any signs of hypersensitivity.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, and it should be avoided in pregnancy and lactation unless absolutely necessary.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT